Abbott Laboratories (ABT) concluded trading on Thursday at a closing price of $133.17, with 5.04 million shares of worth about $671.66 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 19.01% during that period and on February 20, 2025 the price saw a gain of about 0.79%. Currently the company’s common shares owned by public are about 1.73B shares, out of which, 1.72B shares are available for trading.
Stock saw a price change of 2.05% in past 5 days and over the past one month there was a price change of 14.03%. Year-to-date (YTD), ABT shares are showing a performance of 17.73% which increased to 16.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $99.71 but also hit the highest price of $132.65 during that period. The average intraday trading volume for Abbott Laboratories shares is 5.76 million. The stock is currently trading 2.93% above its 20-day simple moving average (SMA20), while that difference is up 10.89% for SMA50 and it goes to 18.09% higher than SMA200.
Abbott Laboratories (NYSE: ABT) currently have 1.73B outstanding shares and institutions hold larger chunk of about 78.70% of that.
The stock has a current market capitalization of $230.98B and its 3Y-monthly beta is at 0.71. PE ratio of stock for trailing 12 months is 17.38, while it has posted earnings per share of $7.66 in the same period. Its PEG reads 1.64 and has Quick Ratio of 1.14 while making debt-to-equity ratio of 0.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABT, volatility over the week remained 1.60% while standing at 2.24% over the month.
Stock’s fiscal year EPS is expected to rise by 10.41% while it is estimated to increase by 10.72% in next year. EPS is likely to shrink at an annualized rate of 10.62% for next 5-years, compared to annual growth of 30.08% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Oppenheimer on October 08, 2024 offering an Outperform rating for the stock and assigned a target price of $130 to it. Coverage by Piper Sandler stated Abbott Laboratories (ABT) stock as an Overweight in their note to investors on September 19, 2024, suggesting a price target of $131 for the stock. On July 30, 2024, Edward Jones Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $121. Stock get a Peer perform rating from Wolfe Research on July 21, 2023.
